DDR, ATR & PARP Inhibitors
January 25-27, 2022
Eurofins Viracor BioPharma will be attending at the DDR 5th Annual PARP, ATR & DDR Inhibitors Summit which is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.
15th WRIB 27 Sept- 1 Oct 2021
27 Sep- 1 Oct 2021
Eurofins will be attending the 15th WRIB and excited to share how our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs — together with testing performed in our high throughput CAP/CLIA laboratory can advance your study design and clinical trial program.
World Vaccine and Immunotherapy Congress 2021
30 Nov- 2 Dec 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the World Vaccine and Immunotherapy Congress and we are excited to share our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs.
6th Annual Oncolytic Virotherapy Summit
26-28 Oct 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the 6th Annual Oncolytic Virotherapy Summit in Boston, October 26-28th, and we are excited to share our latest comprehensive assay offering for next generation sequencing to enable genomic profiling of tumor samples with PanCancerIQ™. Kristen Mickey will be presenting on October 28th "Viral shedding and infectivity testing in clinical trials of oncolytic virotherapies".
Eurofins Viracor BioPharma Immunotherapy Force Multiplier
It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.